0001104659-23-040293.txt : 20230331 0001104659-23-040293.hdr.sgml : 20230331 20230331171258 ACCESSION NUMBER: 0001104659-23-040293 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230331 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001267813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36576 FILM NUMBER: 23789109 BUSINESS ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 484-801-4670 MAIL ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031022 8-K 1 tm2311113d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 31, 2023

Marinus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36576

20-0198082

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer Identification

No.)

5 Radnor Corporate Center, Suite 500

100 Matsonford Rd, Radnor, PA

19087

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (484) 801-4670

__________________________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	MRNS	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

As previously reported, Marinus Pharmaceuticals, Inc. (the “Company”) is a party to that certain Equity Distribution Agreement, dated July 9, 2020 (the “Original Agreement”), between the Company and JMP Securities LLC (the “Agent”). Under the Original Agreement, the Company from time to time may offer and sell shares of its common stock, par value $0.001 per share (the “Common Stock”), having a maximum aggregate offering price of up to $60,000,000 (the “Original Shares”) through the Agent, acting as agent and/or principal. The terms of such offering of Original Shares are contained in a prospectus supplement, dated July 27, 2020, under a Registration Statement on Form S-3 (File No. 333-239780) that was declared effective by the Securities and Exchange Commission (the “SEC”) on July 27, 2020 (the “2020 Registration Statement”) and which expires on July 27, 2023. As of the date hereof, all of the Original Shares remain available to be sold from time to time pursuant to the Original Agreement.

On March 31, 2023, the Company and the Agent entered into Amendment No. 1 (the “Amendment”) to the Original Agreement (as amended, the “Amended Agreement”). Pursuant to the Amended Agreement, the Company from time to time may offer and sell shares of its Common Stock without a maximum aggregate offering price through the Agent, acting as agent and/or principal. The Amendment was entered into in connection with the Company’s filing of a Registration Statement on Form S-3 (File No. 333-271041) with the SEC (the “2023 Registration Statement”), which includes a prospectus supplement covering the offering, issuance and sale by the Company of up to $75,000,000 of shares of Common Stock (the “New Shares”) that may be issued and sold under the Amended Agreement. The New Shares will be offered, issued and sold pursuant to the 2023 Registration Statement once it is declared effective by the SEC. The Original Shares may continue to be issued, offered and sold pursuant to the 2020 Registration Statement until the 2023 Registration Statement is declared effective by the SEC, at which time no shares of Common Stock may be offered, issued or sold under the 2020 Registration Statement.

This description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares of Common Stock nor shall there be any sale of shares of Common Stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Item 8.01. Other Events.

In July 2022, the U.S. Patent and Trademark Office (the “USPTO”) issued a patent to Ovid Therapeutics, Inc. (“Ovid”) with claims that encompass the Company’s product candidate for the treatment of Status Epilepticus (“SE”). On March 15, 2023, the Company filed a petition seeking post-grant review (“PGR”) of Ovid’s U.S. Patent No. 11,395,817 with the United States Patent and Trademark Office Patent Trial and Appeal Board (the “PTAB”). The Company’s petition for PGR argues that the claims of U.S. Patent No. 11,395,817 are unpatentable on multiple grounds as lacking novelty under 35 USC § 102 and being obvious under 35 USC § 103 and, if not invalid under § 102 or § 103, as lacking enablement under 35 USC § 112. Ovid may file a preliminary response to the Company’s petition no later than June 20, 2023, the PTAB will then have up to three months to decide whether to grant the Company’s petition and institute the PGR. In September 2021, the USPTO granted the Company a patent on a method of treating SE, including dosing regimens. This issued patent expires in 2040. This patent is a member of a patent family the Company owns that includes pending patent applications that claim certain therapeutic regimens for the treatment of SE, including Refractory Status Epilepticus, using intravenous ganaxolone.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description
10.1		Amendment No. 1 to the Equity Distribution Agreement, dated as of March 31, 2023, by and between Marinus Pharmaceuticals, Inc. and JMP Securities LLC.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MARINUS PHARMACEUTICALS, INC.

Date: March 31, 2023	/s/ Steven Pfanstiel
	Steven Pfanstiel
	Chief Operating Officer, Chief Financial Officer and Treasurer

EX-10.1 2 tm2311113d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

AMENDMENT NO. 1 TO THE EQUITY DISTRIBUTION AGREEMENT

March 31, 2023

JMP Securities LLC

600 Montgomery Street, Suite 1100

San Francisco, California 94111

Ladies and Gentlemen:

This Amendment No. 1 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and JMP Securities LLC (“Agent”), that are parties to that certain Equity Distribution Agreement dated July 9, 2020 (the “Original Agreement”) and that certain side letter agreement dated July 9, 2020 (the “Side Letter”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

1.            All references to “$60,000,000” in the Original Agreement are hereby deleted in their entirety. In addition, the first sentence of Section 1 “Description of Securities” in the Original Agreement is hereby deleted in its entirety and replaced with the following:

“The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Placement Agent, acting as agent and/or principal, shares (the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), under one or more registration statements on Form S-3 filed with the Commission.”

2.            The Company agrees to pay or cause to be paid all expenses of the Agent, including the fees and expenses of the counsel to the Agent, payable within 30 days of the execution of this Amendment, in an amount not to exceed $30,000.

3.            The Company represents and warrants to, and agrees with the Agent that this Amendment has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.

4.            This Amendment, together with the Original Agreement and the Side Letter (including all schedules and exhibits attached hereto and thereto and Placement Notices issued pursuant hereto and thereto), constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Amendment nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Amendment. All references in the Original Agreement to the “Agreement” shall mean the Original Agreement (together with the Side Letter) as amended by this Amendment; provided, however, that all references to “date of this Agreement” in the Original Agreement shall continue to refer to the date of the Original Agreement.

5.            This Amendment shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Amendment or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. The provisions of this paragraph shall survive any termination of this Amendment.

6.            This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed amendment by one party to the other may be made by facsimile transmission or electronic transmission (e.g., PDF).

[Remainder of Page Intentionally Blank]

If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding amendment to the Original Agreement (together with the Side Letter) between the Company and the Agent.

Very truly yours,

MARINUS PHARMACEUTICALS, INC.

By:	/s/ Steven Pfanstiel

Name:	Steven Pfanstiel
Title:	Chief Financial Officer and Chief Operations Officer

CONFIRMED AND ACCEPTED,
as of the date first above written:

JMP SECURITIES LLC

By:	/s/ David Kellman

Name:	David Kellman
Title:	Managing Director, Head of Healthcare Investment Banking

EX-101.SCH 3 mrns-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mrns-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mrns-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 31, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Entity File Number	001-36576
Entity Registrant Name	Marinus Pharmaceuticals, Inc.
Entity Central Index Key	0001267813
Entity Tax Identification Number	20-0198082
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	5 Radnor Corporate Center
Entity Address, Address Line Two	Suite 500
Entity Address, Address Line Three	100 Matsonford Rd
Entity Address, City or Town	Radnor
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	484
Local Phone Number	801-4670
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	MRNS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2311113d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001267813 2023-03-31 2023-03-31 iso4217:USD shares iso4217:USD shares 0001267813 false 8-K 2023-03-31 Marinus Pharmaceuticals, Inc. DE 001-36576 20-0198082 5 Radnor Corporate Center Suite 500 100 Matsonford Rd Radnor PA 19087 484 801-4670 false false false false Common Stock, par value $0.001 MRNS NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://marinuspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2311113d1_8k.htm mrns-20230331.xsd mrns-20230331_lab.xml mrns-20230331_pre.xml tm2311113d1_ex10-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2311113d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2311113d1_8k.htm" ] }, "labelLink": { "local": [ "mrns-20230331_lab.xml" ] }, "presentationLink": { "local": [ "mrns-20230331_pre.xml" ] }, "schema": { "local": [ "mrns-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrns", "nsuri": "http://marinuspharma.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2311113d1_8k.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://marinuspharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2311113d1_8k.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marinuspharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-040293-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-040293-xbrl.zip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